<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="wordpress.com" -->
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd"
	xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
	xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
	xmlns:image="http://www.google.com/schemas/sitemap-image/1.1"
	>
<url><loc>https://copywritersalute.com/2026/09/11/farmacoresistenza-in-epilessia-oggi/</loc><news:news><news:publication><news:name>Comunicare Salute</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-09-11T16:56:15+00:00</news:publication_date><news:title>Farmacoresistenza in epilessia, oggi</news:title><news:keywords>aderenza terapeutica, dieta chetogenica, epilessia, farmacoresistenza, cannabidiolo, Sudep, sindrome di Lennox-Gastaut, fenfluramina, cenobamato, sclerosi tuberosa, farmaci anticrisi, epilessia farmacoresistente, ASM, Edoardo Ferlazzo, rational polytherapy, encefalopatie epilettiche e dello sviluppo, DEE, deficit di GLUT1, GLUT1, inibitori di mTOR, oligonucleotidi antisenso, LITT, stereoelettroencefalografia, SEEG, termocoagulazione, neuromodulazione, stimolazione cerebrale profonda, neurostimolazione responsiva, stimolazione del nervo vago, DBS, RNS, VNS, ipotesi dei trasportatori, P-glicoproteina, Pgp, biomarcatori</news:keywords></news:news><image:image><image:loc>https://copywritersalute.com/wp-content/uploads/2026/09/epilessia-farmacoresistente-farmacoresistenza-farmaci-anticrisi-asm.jpg?w=150</image:loc></image:image></url></urlset>
